A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Starpharma
- 27 Feb 2019 Interim results published in the Media Release
- 26 Feb 2018 According to a Starpharma media release, two UK sites have been already activated for recruitment and additional sites to follow in the expansion phase.
- 26 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Starpharma media release.